Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 10, 2016 - Issue
Submit an article Journal homepage
73
Views
10
CrossRef citations to date
0
Altmetric
Original Research

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma

Cong Xue1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, People’s Republic of China
,
Ying Tian2 Department of Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, People’s Republic of China
,
Jing Zhang3 Department of Medical Oncology, The First Affiliated Hospital of Guangzhou Traditional Chinese Medicine University, Guangzhou, Guangdong, People’s Republic of China
,
Yuanyuan Zhao1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, People’s Republic of China
,
Jianhua Zhan2 Department of Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, People’s Republic of China
,
Wenfeng Fang1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, People’s Republic of China
&
Li Zhang1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 1299-1306 | Published online: 31 Mar 2016

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Gang Gui, Ziqi Fan, Yihuan Ning, Cancan Yuan, Baolin Zhang & Qin Xu. (2021) Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles. International Journal of Nanomedicine 16, pages 2283-2295.
Read now
Ruilong Lan, Fei Huang, Guangxian Zhong, Ruiqing Chen, Zeng Wang, Junying Chen, Lengxi Fu, Jinsheng Hong & Lurong Zhang. (2019) Effects of CKMT1 on radiosensitivity of nasopharyngeal carcinoma cells. International Journal of Radiation Biology 95:5, pages 597-606.
Read now
Brigette B.Y. Ma, Edwin P Hui & Anthony T.C. Chan. (2017) Investigational drugs for nasopharyngeal carcinoma. Expert Opinion on Investigational Drugs 26:6, pages 677-685.
Read now

Articles from other publishers (7)

Nina Shaban, Dmitri Kamashev, Aleksandra Emelianova & Anton Buzdin. (2023) Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells 13:1, pages 47.
Crossref
Xintong Peng, Yanling Zhou, Yongguang Tao & Shuang Liu. (2021) Nasopharyngeal Carcinoma: The Role of the EGFR in Epstein–Barr Virus Infection. Pathogens 10:9, pages 1113.
Crossref
Hsin-Pai Li, Chen-Yang Huang, Kar-Wai Lui, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yenlin Huang, Tung-Liang Lin, Yung-Chia Kuo, Mei-Yuan Huang, Yi-Ru Lai, Yuan-Ming Yeh, Hsien-Chi Fan, An-Chi Lin, Jason Chia-Hsun Hsieh, Kai-Ping Chang, Chien-Yu Lin, Hung-Ming Wang, Yu-Sun Chang & Cheng-Lung Hsu. (2021) Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment. Cancers 13:12, pages 2954.
Crossref
Sufang Qiu, Miaomiao Li, Jun Liu, Xiaochuan Chen, Ting Lin, Yunchao Xu, Yang Chen, Youliang Weng, Yuhui Pan, Shangyuan Feng, Xiandong Lin, Lurong Zhang & Duo Lin. (2020) Study on the chemodrug-induced effect in nasopharyngeal carcinoma cells using laser tweezer Raman spectroscopy. Biomedical Optics Express 11:4, pages 1819.
Crossref
Sandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, Jaafar Bennouna, Mouna Sassi, Hélène de Mont-Serrat, Jean Fan, David Schnell & Jean-Pierre Delord. (2018) Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Investigational New Drugs 36:6, pages 1044-1059.
Crossref
Eleonore Longton, Kathleen Schmit, Maude Fransolet, François Clement & Carine Michiels. (2018) Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology 8.
Crossref
Helga Wecker & Cornelius F. Waller. 2018. Small Molecules in Oncology. Small Molecules in Oncology 199 215 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.